Literature DB >> 8550840

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.

D T Eitzman1, R D McCoy, X Zheng, W P Fay, T Shen, D Ginsburg, R H Simon.   

Abstract

Impaired fibrinolytic activity within the lung is a common manifestation of acute and chronic inflammatory lung diseases. Because the fibrinolytic system is active during repair processes that restore injured tissues to normal, reduced fibrinolytic activity may contribute to the subsequent development of pulmonary fibrosis. To examine the relationship between the fibrinolytic system and pulmonary fibrosis, lung inflammation was induced by bleomycin in transgenic mice that either overexpressed or were completely deficient in murine plasminogen activator inhibitor-1 (PAI-1). 2 wk after 0.075 U of bleomycin, the lungs of transgenic mice overexpressing PAI-1 contained significantly more hydroxyproline (118 +/- 8 micrograms) than littermate controls (70.5 +/- 8 micrograms, P < 0.005). 3 wk after administration of a higher dose of bleomycin (0.15 U), the lung hydroxyproline content of mice completely deficient in PAI-1 (49 +/- 8 micrograms) was not significantly different (P = 0.63) than that of control animals receiving saline (37 +/- 1 micrograms), while hydroxyproline content was significantly increased in heterozygote (77 +/- 12 micrograms, P = 0.06) and wild-type (124 +/- 19 micrograms, P < 0.001) littermates. These data demonstrate a direct correlation between the genetically determined level of PAI-1 expression and the extent of collagen accumulation that follows inflammatory lung injury. These results strongly support the hypothesis that alterations in fibrinolytic activity influence the extent of pulmonary fibrosis that occurs after inflammatory injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550840      PMCID: PMC507084          DOI: 10.1172/JCI118396

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B.

Authors:  R M Senior; W F Skogen; G L Griffin; G D Wilner
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  The intensity of chronic lung inflammation and fibrosis after bleomycin is directly related to the severity of acute injury.

Authors:  A S Shen; C Haslett; D C Feldsien; P M Henson; R M Cherniack
Journal:  Am Rev Respir Dis       Date:  1988-03

5.  Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis.

Authors:  S Idell; K K Gonzalez; C K MacArthur; C Gillies; P N Walsh; J McLarty; R S Thrall
Journal:  Am Rev Respir Dis       Date:  1987-07

Review 6.  Type 1 plasminogen activator inhibitor.

Authors:  D J Loskutoff; M Sawdey; J Mimuro
Journal:  Prog Hemost Thromb       Date:  1989

Review 7.  Growth factors in the regulation of pericellular proteolysis: a review.

Authors:  M Laiho; J Keski-Oja
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

8.  Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage.

Authors:  S Idell; J Peters; K K James; D S Fair; J J Coalson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

9.  Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis.

Authors:  J D Hasday; P R Bachwich; J P Lynch; R G Sitrin
Journal:  Exp Lung Res       Date:  1988       Impact factor: 2.459

10.  Intraluminal fibrosis in interstitial lung disorders.

Authors:  F Basset; V J Ferrans; P Soler; T Takemura; Y Fukuda; R G Crystal
Journal:  Am J Pathol       Date:  1986-03       Impact factor: 4.307

View more
  164 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  PAI-1, fibrosis, and the elusive provisional fibrin matrix.

Authors:  D J Loskutoff; J P Quigley
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

3.  A Fas pathway to pulmonary fibrosis.

Authors:  H A Chapman
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

4.  Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis.

Authors:  N Kaminski; J D Allard; J F Pittet; F Zuo; M J Griffiths; D Morris; X Huang; D Sheppard; R A Heller
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 5.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 6.  Importance of mast cells in the pathophysiology of asthma.

Authors:  Seong H Cho; Andrea J Anderson; Chad K Oh
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

7.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

8.  Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin.

Authors:  T Betsuyaku; Y Fukuda; W C Parks; J M Shipley; R M Senior
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 9.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

10.  Regulation of alveolar epithelial cell apoptosis and pulmonary fibrosis by coordinate expression of components of the fibrinolytic system.

Authors:  Yashodhar P Bhandary; Shwetha K Shetty; Amarnath S Marudamuthu; Margaret R Gyetko; Steven Idell; Mehrnaz Gharaee-Kermani; Rashmi S Shetty; Barry C Starcher; Sreerama Shetty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-02       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.